JP6401172B2 - 貧血の治療方法 - Google Patents

貧血の治療方法 Download PDF

Info

Publication number
JP6401172B2
JP6401172B2 JP2015539751A JP2015539751A JP6401172B2 JP 6401172 B2 JP6401172 B2 JP 6401172B2 JP 2015539751 A JP2015539751 A JP 2015539751A JP 2015539751 A JP2015539751 A JP 2015539751A JP 6401172 B2 JP6401172 B2 JP 6401172B2
Authority
JP
Japan
Prior art keywords
gdf11
seq
actriia
polypeptide
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015539751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503398A (ja
JP2016503398A5 (enExample
Inventor
スング ビクトリア
スング ビクトリア
チョプラ ラジェシュ
チョプラ ラジェシュ
ヘルミネ オリビエル
ヘルミネ オリビエル
クルズモウラ イバン
クルズモウラ イバン
ドウシオト ミチャエル
ドウシオト ミチャエル
トロバトイマシエル トヒアゴ
トロバトイマシエル トヒアゴ
フリコト アウレリエ
フリコト アウレリエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2016503398A publication Critical patent/JP2016503398A/ja
Publication of JP2016503398A5 publication Critical patent/JP2016503398A5/ja
Application granted granted Critical
Publication of JP6401172B2 publication Critical patent/JP6401172B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015539751A 2012-10-24 2013-10-23 貧血の治療方法 Active JP6401172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718128P 2012-10-24 2012-10-24
US61/718,128 2012-10-24
PCT/US2013/066353 WO2014066487A2 (en) 2012-10-24 2013-10-23 Methods for treating anemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018131952A Division JP2018184430A (ja) 2012-10-24 2018-07-12 貧血の治療方法

Publications (3)

Publication Number Publication Date
JP2016503398A JP2016503398A (ja) 2016-02-04
JP2016503398A5 JP2016503398A5 (enExample) 2016-12-08
JP6401172B2 true JP6401172B2 (ja) 2018-10-10

Family

ID=50545463

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015539751A Active JP6401172B2 (ja) 2012-10-24 2013-10-23 貧血の治療方法
JP2018131952A Pending JP2018184430A (ja) 2012-10-24 2018-07-12 貧血の治療方法
JP2020108654A Withdrawn JP2020183390A (ja) 2012-10-24 2020-06-24 貧血の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018131952A Pending JP2018184430A (ja) 2012-10-24 2018-07-12 貧血の治療方法
JP2020108654A Withdrawn JP2020183390A (ja) 2012-10-24 2020-06-24 貧血の治療方法

Country Status (9)

Country Link
US (1) US20150266950A1 (enExample)
EP (2) EP2911682A4 (enExample)
JP (3) JP6401172B2 (enExample)
CN (3) CN112957462A (enExample)
AU (4) AU2013334660B2 (enExample)
CA (1) CA2889286A1 (enExample)
HK (1) HK1214504A1 (enExample)
NZ (1) NZ747350A (enExample)
WO (1) WO2014066487A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020183390A (ja) * 2012-10-24 2020-11-12 セルジーン コーポレイション 貧血の治療方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA015105B1 (ru) 2005-11-23 2011-06-30 Акселерон Фарма Инк. Антагонисты активина - actriia и их применение для стимулирования роста кости
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN107050424A (zh) 2007-02-01 2017-08-18 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW202104248A (zh) 2007-02-02 2021-02-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
TWI748373B (zh) 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
MX387164B (es) 2009-06-12 2025-03-19 Acceleron Pharma Inc Proteínas de fusión actriib-fc truncadas.
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
EP3308796B1 (en) 2012-11-02 2021-07-14 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
KR102520970B1 (ko) * 2014-03-21 2023-04-12 악셀레론 파마 인코포레이티드 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
US20180031579A1 (en) * 2015-02-12 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
TWI814187B (zh) * 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
MD3496739T2 (ro) 2016-07-15 2021-09-30 Acceleron Pharma Inc Compoziții care cuprind polipeptide actriia pentru utilizarea în tratarea hipertensiunii pulmonare
PT3490582T (pt) 2016-07-27 2024-08-21 Acceleron Pharma Inc Composições para utilização no tratamento da mielofibrose
CA3043180A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN107011430B (zh) * 2017-04-07 2020-09-01 哈尔滨医科大学 一种具有生物学活性的截短的生长分化因子11及其制备方法
KR20250059538A (ko) 2017-11-09 2025-05-02 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
AU2019206634B2 (en) 2018-01-12 2024-06-27 Keros Therapeutics, Inc. Activin receptor type IIB variants and methods of use thereof
JP7405772B2 (ja) * 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
WO2020257587A1 (en) * 2019-06-19 2020-12-24 Cornell University Methods of promoting erythropoiesis and overcoming erythropoitein resistance in patients
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
CN113801880B (zh) * 2021-07-27 2024-11-01 浙江大学 一种通过靶向敲除基因建立的早衰细胞模型及其sgRNA、构建方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
CA2194660C (en) * 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US7795202B2 (en) 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
NZ528341A (en) * 1998-07-28 2005-06-24 Univ Johns Hopkins Med Use of reagents that affect growth differentiation factor-11 (GDF-11) to treat chronic or acute renal disease
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7572763B2 (en) 2002-02-21 2009-08-11 Wyeth Follistatin domain containing proteins
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
EP2314617B1 (en) 2004-07-23 2015-06-24 Acceleron Pharma Inc. ActRII receptor polypeptides
WO2006105359A2 (en) * 2005-03-30 2006-10-05 Wyeth Methods for stimulating hair growth by administering bmps
US7612040B2 (en) * 2005-07-01 2009-11-03 Acceleron Pharma Inc. Lefty polypeptides and derivatives thereof
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
NZ577847A (en) * 2006-12-18 2012-06-29 Acceleron Pharma Inc Activin-actrii antagonists and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TW202104248A (zh) 2007-02-02 2021-02-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US8236751B2 (en) 2007-03-07 2012-08-07 The Johns Hopkins University Methods of increasing muscle mass using follistatin-like related gene (FLRG)
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
AU2009262968A1 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Antagonists of activin-ActRIIa and uses for increasing red blood cell levels
TWI748373B (zh) * 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP3838919A1 (en) * 2009-08-13 2021-06-23 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2012027065A2 (en) * 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
CN103298832A (zh) * 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
HK1214504A1 (zh) * 2012-10-24 2016-07-29 细胞基因公司 用於治療貧血的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020183390A (ja) * 2012-10-24 2020-11-12 セルジーン コーポレイション 貧血の治療方法

Also Published As

Publication number Publication date
JP2016503398A (ja) 2016-02-04
AU2022201923A1 (en) 2022-04-14
NZ747350A (en) 2020-07-31
HK1214504A1 (zh) 2016-07-29
AU2020203198A1 (en) 2020-06-11
AU2018256635A1 (en) 2018-11-22
JP2020183390A (ja) 2020-11-12
AU2013334660B2 (en) 2018-08-09
CN112957462A (zh) 2021-06-15
WO2014066487A3 (en) 2014-06-19
EP2911682A4 (en) 2016-03-23
EP2911682A2 (en) 2015-09-02
AU2020203198B2 (en) 2021-12-23
US20150266950A1 (en) 2015-09-24
CN112933223A (zh) 2021-06-11
AU2013334660A1 (en) 2015-05-14
JP2018184430A (ja) 2018-11-22
CN104981250A (zh) 2015-10-14
WO2014066487A2 (en) 2014-05-01
EP3527219A1 (en) 2019-08-21
CA2889286A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
JP6401172B2 (ja) 貧血の治療方法
JP7146850B2 (ja) 貧血の治療に使用するためのバイオマーカー
AU2016203098B2 (en) Antagonists of activin-ActRIIa and uses for increasing red blood cell levels
JP2018087828A (ja) アクチビン−ＡｃｔＲＩＩａアンタゴニストを投薬する方法および処置される患者をモニターする方法
HK40012688A (en) Methods for treating anemia
HK40023193A (en) Biomarker for use in treating anemia
HK1213948B (en) Biomarker for use in treating anemia
NZ743635B2 (en) Biomarker for use in treating anemia
NZ743635A (en) Biomarker for use in treating anemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180712

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180906

R150 Certificate of patent or registration of utility model

Ref document number: 6401172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250